Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Is Most-Watched Stock Vertex Pharmaceuticals Incorporated (VRTX) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $284.44, moving +1.88% from the previous trading session.
Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More
by Zacks Equity Research
Regulatory and acquisition updates from Gilead (GILD) and Forma (FMTX) are key highlights from the biotech sector during the past week.
Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CLRG
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
CRISPR Therapeutics' (CRSP) Pipeline Development Fuels Growth
by Zacks Equity Research
While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.
Vertex (VRTX) CF Drug Gets FDA Expanded Label for Toddlers
by Zacks Equity Research
Following FDA approval for label expansion, Vertex Pharmaceuticals' (VRTX) Orkambi is now approved for treating cystic fibrosis in children aged one year and older.
Is IQ Chaikin U.S. Large Cap ETF (CLRG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CLRG
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
The Zacks Analyst Blog Highlights Mastercard, Cisco, PayPal, Vertex Pharmaceuticals and ICICI Bank
by Zacks Equity Research
Mastercard, Cisco, PayPal, Vertex Pharmaceuticals and ICICI Bank are included in this Analyst Blog.
Top Stock Reports for Mastercard, Cisco & PayPal
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), Cisco Systems, Inc. (CSCO) and PayPal Holdings, Inc. (PYPL).
Vertex (VRTX) Stock Up 36% This Year So Far: What Lies Ahead?
by Zacks Equity Research
Vertex's (VRTX) CF sales rise 22% in the first half of 2022, primarily driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.
The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals
by Zacks Equity Research
Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates
by Zacks Equity Research
Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.
CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.
Vertex (VRTX) Beats on Q2 Earnings, Ups 2022 Sales Guidance
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) Q2 earnings and sales beat estimates. The company increases its revenue guidance for 2022.
Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 3.45% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings on Aug 4: LLY, AMGN & More
by Kinjel Shah
Let us look at four large drug and biotech companies, AMGN, VRTX, LLY, NVO, which are gearing up for their earnings release.
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.2% Jump Turn into More Strength?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex Pharmaceuticals' (VRTX) Q2 earnings call, investors are most likely to focus on the sales performance of its cystic fibrosis (CF) medicines and updates on its non-CF pipeline candidates.
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?